Tags

Type your tag names separated by a space and hit enter

Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group.
Arthritis Rheum. 1999 Jun; 42(6):1246-54.AR

Abstract

OBJECTIVE

To investigate whether the incidence of vertebral fractures is related to the magnitude of change in bone mineral density (BMD) during alendronate treatment.

METHODS

Women in this study were age 55-81 years (n = 2,984). While participating in the Fracture Intervention Trial, they received 5 mg/day of alendronate for 2 years followed by 10 mg/day for the remaining 12-30 months of the study. Their BMD was measured at baseline and at 12 and 24 months, and spine radiographs were obtained at baseline and again at 36 or 48 months to identify new vertebral fractures.

RESULTS

After 12 months of alendronate treatment, 35% of participants had increases of > or =3% in total hip BMD, and 21% had either decreased total hip BMD or no change. Women who had larger increases in total hip BMD during the first 12 months had a lower incidence of new vertebral fractures during the entire followup period. Only 3.2% of women with increases of > or =3% in total hip BMD experienced new vertebral fractures, whereas twice as many women (6.3%) whose BMD declined or stayed the same experienced new fractures (adjusted odds ratio 0.45, 95% confidence interval 0.27-0.72). Similar patterns were observed for spine BMD at 12 months, and for both sites using change in BMD at 24 months.

CONCLUSION

Women with increases of > or =3% in BMD during the first 1 or 2 years of alendronate treatment had the lowest incidence of new vertebral fractures. These findings suggest that, among women taking antiresorptive agents, greater increases in BMD are associated with lower risk of new vertebral fractures.

Authors+Show Affiliations

University of Maryland School of Medicine, Baltimore, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

10366118

Citation

Hochberg, M C., et al. "Larger Increases in Bone Mineral Density During Alendronate Therapy Are Associated With a Lower Risk of New Vertebral Fractures in Women With Postmenopausal Osteoporosis. Fracture Intervention Trial Research Group." Arthritis and Rheumatism, vol. 42, no. 6, 1999, pp. 1246-54.
Hochberg MC, Ross PD, Black D, et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum. 1999;42(6):1246-54.
Hochberg, M. C., Ross, P. D., Black, D., Cummings, S. R., Genant, H. K., Nevitt, M. C., Barrett-Connor, E., Musliner, T., & Thompson, D. (1999). Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis and Rheumatism, 42(6), 1246-54.
Hochberg MC, et al. Larger Increases in Bone Mineral Density During Alendronate Therapy Are Associated With a Lower Risk of New Vertebral Fractures in Women With Postmenopausal Osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum. 1999;42(6):1246-54. PubMed PMID: 10366118.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. AU - Hochberg,M C, AU - Ross,P D, AU - Black,D, AU - Cummings,S R, AU - Genant,H K, AU - Nevitt,M C, AU - Barrett-Connor,E, AU - Musliner,T, AU - Thompson,D, PY - 1999/6/12/pubmed PY - 1999/6/12/medline PY - 1999/6/12/entrez KW - Non-programmatic SP - 1246 EP - 54 JF - Arthritis and rheumatism JO - Arthritis Rheum. VL - 42 IS - 6 N2 - OBJECTIVE: To investigate whether the incidence of vertebral fractures is related to the magnitude of change in bone mineral density (BMD) during alendronate treatment. METHODS: Women in this study were age 55-81 years (n = 2,984). While participating in the Fracture Intervention Trial, they received 5 mg/day of alendronate for 2 years followed by 10 mg/day for the remaining 12-30 months of the study. Their BMD was measured at baseline and at 12 and 24 months, and spine radiographs were obtained at baseline and again at 36 or 48 months to identify new vertebral fractures. RESULTS: After 12 months of alendronate treatment, 35% of participants had increases of > or =3% in total hip BMD, and 21% had either decreased total hip BMD or no change. Women who had larger increases in total hip BMD during the first 12 months had a lower incidence of new vertebral fractures during the entire followup period. Only 3.2% of women with increases of > or =3% in total hip BMD experienced new vertebral fractures, whereas twice as many women (6.3%) whose BMD declined or stayed the same experienced new fractures (adjusted odds ratio 0.45, 95% confidence interval 0.27-0.72). Similar patterns were observed for spine BMD at 12 months, and for both sites using change in BMD at 24 months. CONCLUSION: Women with increases of > or =3% in BMD during the first 1 or 2 years of alendronate treatment had the lowest incidence of new vertebral fractures. These findings suggest that, among women taking antiresorptive agents, greater increases in BMD are associated with lower risk of new vertebral fractures. SN - 0004-3591 UR - https://www.unboundmedicine.com/medline/citation/10366118/Larger_increases_in_bone_mineral_density_during_alendronate_therapy_are_associated_with_a_lower_risk_of_new_vertebral_fractures_in_women_with_postmenopausal_osteoporosis__Fracture_Intervention_Trial_Research_Group_ L2 - https://doi.org/10.1002/1529-0131(199906)42:6<1246::AID-ANR22>3.0.CO;2-U DB - PRIME DP - Unbound Medicine ER -